Pterostilbene for Health & Longevity

Evidence Review created on 04/17/2026 using AI4L / Opus 4.7

Motivation

Pterostilbene is a plant compound found primarily in blueberries and grapes, and it is closely related in structure to resveratrol. Interest in pterostilbene within the longevity community stems from two features: its reported ability to activate the same anti-aging molecular pathways as resveratrol, and its substantially higher oral absorption, which addresses the central weakness of resveratrol supplementation.

Historically, pterostilbene attracted researchers as a “better resveratrol” — one that might deliver the benefits suggested by decades of laboratory research without the absorption limits that have hampered resveratrol in clinical studies. In humans, a small number of controlled trials have examined effects on blood pressure, cholesterol, and cellular energy metabolism, though the human outcome base remains strikingly modest. Pterostilbene is also a key ingredient in commercial cellular-energy-boosting products combined with nicotinamide riboside.

This review examines the current human evidence for pterostilbene, its proposed mechanisms, and the gap between how well it is absorbed by the body and the still-limited clinical data on health and longevity outcomes.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Pterostilbene - Grokipedia

Dedicated page covering pterostilbene’s chemistry as a dimethylated analog of resveratrol, its biosynthesis by the enzyme resveratrol O-methyltransferase (ROMT), natural sources (blueberries, grapes, Pterocarpus marsupium heartwood, almonds), and biological activities including ROS scavenging and Nrf2 pathway activation. Also addresses its higher lipophilicity and oral bioavailability relative to resveratrol.

Examine

Pterostilbene - Examine

Dedicated Examine.com supplement monograph on pterostilbene covering its relationship to resveratrol, absorption advantages, the single human trial’s LDL and blood-pressure findings, and evidence grades across outcomes. Useful as a standardized, continuously updated reference on the human data.

ConsumerLab

No dedicated ConsumerLab review of pterostilbene as a standalone supplement was found. ConsumerLab coverage of pterostilbene-containing products appears primarily in the context of the Elysium Health Basis product (nicotinamide riboside plus pterostilbene) within its broader NAD+/Niagen review.

Systematic Reviews

A summary of systematic reviews and meta-analyses evaluating pterostilbene supplementation from PubMed.

The Effect of Pterostilbene and Its Active Ingredients on Experimental Pulmonary Fibrosis in Asthma: A Meta-Analysis - Peng et al., 2022

Meta-analysis of 7 randomized animal studies (62 total animals) examining pterostilbene’s effects on oxidative damage markers — showing up-regulation of superoxide dismutase (SOD) and glutathione (GSH) and down-regulation of malondialdehyde (MDA) — limited to preclinical data with no direct human clinical relevance established.

No large human-focused systematic reviews or meta-analyses of pterostilbene for cardiovascular, metabolic, cognitive, or longevity outcomes were found on PubMed as of 04/17/2026. The evidence base is still dominated by narrative reviews and individual primary trials.

Mechanism of Action

Pterostilbene is a naturally occurring stilbenoid — specifically, the 3,5-dimethoxy analog of resveratrol. Its two methoxy groups (–OCH₃) replace the hydroxyl groups at the 3 and 5 positions of resveratrol, which dramatically changes its pharmacokinetic profile: pterostilbene is more lipophilic (fat-soluble), more resistant to first-pass conjugation in the gut and liver, and reaches plasma concentrations roughly 4-fold higher than equivalent doses of resveratrol.

The most cited mechanism is activation of sirtuins, particularly SIRT1 — a NAD+ (nicotinamide adenine dinucleotide, a coenzyme required for sirtuin catalytic activity)-dependent histone deacetylase implicated in stress resistance, metabolic regulation, and longevity. Like resveratrol, pterostilbene is classified as a sirtuin-activating compound (STAC). The same caveat applies: recent work questions whether human-achievable plasma concentrations produce meaningful SIRT1 activation in vivo.

Pterostilbene also activates AMPK (AMP-activated protein kinase, a cellular energy sensor that promotes catabolic pathways and inhibits anabolic pathways when cellular energy is low), which in turn suppresses mTOR (mechanistic target of rapamycin, a signaling pathway that drives cell growth and protein synthesis). This AMPK/mTOR modulation is a core part of the proposed caloric-restriction-mimetic mechanism.

As an antioxidant, pterostilbene scavenges reactive oxygen species (ROS) directly and activates Nrf2 (nuclear factor erythroid 2-related factor 2, a transcription factor that induces endogenous antioxidant and detoxification enzymes), up-regulating glutathione, superoxide dismutase (SOD), and catalase. It also inhibits NF-κB (nuclear factor kappa B, a master regulator of inflammatory gene expression) signaling, reducing pro-inflammatory cytokines including IL-6 (interleukin-6) and TNF-α (tumor necrosis factor alpha).

In the cardiovascular system, pterostilbene modulates the PCSK9/HNF1α/SREBP2/LDLR axis in cardiomyocytes, up-regulating LDL receptor expression — a mechanistically interesting finding, but one that paradoxically coincides with elevated circulating LDL-cholesterol in the principal human trial, suggesting complex lipoprotein handling that is not fully understood.

Competing mechanistic interpretations exist. Proponents emphasize pterostilbene’s superior bioavailability and evidence of sirtuin/AMPK activation at physiologically plausible concentrations. Skeptics note that much of the mechanistic evidence comes from concentrations far exceeding those achievable through oral supplementation in humans, and that the cardiovascular lipid signal in human trials raises questions about whether the net effect of the biochemistry is beneficial.

Historical Context & Evolution

Pterostilbene was first identified in the heartwood of Pterocarpus marsupium (Indian kino tree), whose use in traditional Ayurvedic medicine for diabetes, inflammation, and digestive conditions dates back centuries. The compound’s name derives from this genus. It was later identified as a natural constituent of blueberries, grapes, and almonds.

Serious interest in pterostilbene as a health supplement emerged in the 2000s, riding the coattails of resveratrol’s prominence. After the 2003 Sinclair et al. publication on resveratrol and sirtuins launched the polyphenol-longevity field, researchers began investigating whether pterostilbene’s superior bioavailability might yield stronger effects. Early pharmacokinetic work established that pterostilbene reaches plasma concentrations several-fold higher than equivalent doses of resveratrol and has a longer half-life.

The first human clinical trial, Riche et al. (2013), assessed safety and found pterostilbene well-tolerated at up to 250 mg/day. The follow-up metabolic trial (Riche et al., 2014) reported reduced blood pressure but, unexpectedly, increased LDL cholesterol with pterostilbene monotherapy — a finding that prompted supplement producer ChromaDex to cease new pterostilbene orders at the time and remains the single most discussed safety signal for the compound.

Commercial interest in pterostilbene surged after Elysium Health launched Basis in 2015, combining pterostilbene with nicotinamide riboside to raise NAD+ levels. The NRPT (NR + PT) trials demonstrated sustained NAD+ elevation and hepatic inflammation improvement in non-alcoholic fatty liver disease (NAFLD, a chronic condition of fat accumulation in the liver unrelated to alcohol use), but primary endpoints — hepatic fat fraction in NAFLD, and clinical outcomes in amyotrophic lateral sclerosis (ALS) — have generally not met statistical targets. Whether the observed biomarker improvements translate into meaningful clinical benefit remains unresolved.

The field’s current position is cautious optimism among enthusiasts and substantial skepticism among longevity-focused clinicians such as Peter Attia, with general agreement that the compound’s bioavailability advantages over resveratrol are real but that the human outcome evidence remains thin.

Expected Benefits

Medium 🟩 🟩

Blood Pressure Reduction

Riche et al. (2014) demonstrated in an 80-participant randomized controlled trial (RCT) that high-dose pterostilbene (125 mg twice daily, 250 mg/day total) significantly reduced systolic blood pressure by approximately 7.8 mmHg and diastolic blood pressure by approximately 7.3 mmHg over 6–8 weeks. This is among the larger blood-pressure effects reported for any polyphenol supplement and compares favorably with first-line antihypertensive medications at low doses. The effect was most pronounced at the higher dose and in participants not on cholesterol medications. The single-trial basis limits confidence, but the magnitude and statistical robustness support a Medium evidence grade.

Magnitude: Approximately −7.8 mmHg systolic and −7.3 mmHg diastolic at 250 mg/day over 6–8 weeks in adults with hypercholesterolemia.

NAD+ Elevation (as Part of NRPT Combination)

Dellinger et al. (2017) demonstrated in a 120-participant RCT in healthy adults aged 60–80 that nicotinamide riboside combined with pterostilbene (NRPT, marketed as Basis) increased whole-blood NAD+ by approximately 40% at the recommended dose and approximately 90% at the double dose, sustained over 8 weeks. While the NAD+ increase is driven primarily by nicotinamide riboside, pterostilbene is included specifically to activate sirtuins that consume NAD+. This represents a consistent, reproducible biomarker effect, though the clinical significance of raised NAD+ without demonstrated outcome benefits remains debated.

Magnitude: +40% whole-blood NAD+ at 250 mg nicotinamide riboside + 50 mg pterostilbene daily; +90% at the double dose (500 mg + 100 mg daily).

Low 🟩

Hepatic Inflammation Reduction in NAFLD ⚠️ Conflicted

Dellinger et al. (2023) reported in a 6-month, 111-participant RCT in non-alcoholic fatty liver disease (NAFLD) that NRPT at the recommended dose produced time-dependent reductions in alanine aminotransferase (ALT, a liver enzyme that rises when hepatocytes are damaged), gamma-glutamyl transferase (GGT, a liver/biliary enzyme sensitive to hepatobiliary injury and alcohol), and the toxic lipid ceramide 14:0 — all secondary endpoints. However, the primary endpoint (hepatic fat fraction) was not met, and the higher dose paradoxically did not produce the same biomarker improvements. Critics including Peter Attia have noted this pattern and argue the primary-endpoint failure is more informative than the secondary findings.

Magnitude: Modest reductions in ALT and GGT at the single recommended dose; no significant reduction in hepatic fat. Conflicted interpretation regarding clinical meaningfulness.

Antioxidant and Anti-Inflammatory Activity

Pterostilbene demonstrates reproducible up-regulation of endogenous antioxidants (SOD, glutathione, catalase) and down-regulation of markers of oxidative damage (malondialdehyde) in animal models — Peng et al. (2022) meta-analyzed 7 animal studies and found consistent effects. Limited human biomarker data exist. For healthy adults, the clinical translation of these antioxidant effects remains uncertain, and whether chronic up-regulation of endogenous antioxidants delivers meaningful health benefit is itself debated.

Magnitude: In animal studies, SOD mean difference approximately +20 units; malondialdehyde significantly decreased. Human data are sparse and largely indirect.

Speculative 🟨

Sirtuin Activation & Longevity Pathway Modulation ⚠️ Conflicted

Pterostilbene is proposed as a sirtuin-activating compound (STAC) that mimics some effects of caloric restriction. In Drosophila, pterostilbene extended mean lifespan in both sexes and modulated expression of longevity-associated genes (Sir2, Foxo, Notch). Rodent data show metabolic and neuroprotective effects. However, no human data exist demonstrating lifespan or healthspan extension, and recent work questioning sirtuin activation by stilbenoids at human-achievable concentrations applies here as it does for resveratrol.

Cognitive Function & Neuroprotection ⚠️ Conflicted

In vitro and rodent studies suggest pterostilbene crosses the blood-brain barrier, reduces neuroinflammation, activates brain-derived neurotrophic factor (BDNF)-related pathways, and improves cognitive performance in aged animals. Human evidence is limited. Small pilot trials in ALS (EH301, the NR-pterostilbene combination) have shown mixed results, with some slowing of functional decline but inconsistent outcomes across studies.

Anti-Cancer Properties ⚠️ Conflicted

Pterostilbene demonstrates extensive in vitro anti-cancer activity across multiple cancer cell lines and reduces tumor growth in rodent models through modulation of apoptosis, cell cycle, and inflammatory signaling. Human cancer prevention or treatment data are absent. A phase 2 trial (NCT03671811) is examining pterostilbene as an adjunct to megestrol acetate in endometrial cancer, but results have not been published in peer-reviewed form.

Skin Photoaging & Cosmetic Benefits

In vitro work and a 2025 MDPI in-vitro evaluation suggest pterostilbene may protect against UV-induced skin damage by modulating ROS and senescence markers. No controlled human trials support cosmetic or photoaging benefits at this time.

Benefit-Modifying Factors

Bioavailability advantage: Pterostilbene’s two methoxy groups confer approximately 4-fold higher oral bioavailability than resveratrol (roughly 80% vs. 20% in preclinical models) and a longer plasma half-life. This is the principal reason practitioners consider pterostilbene over resveratrol despite resveratrol’s larger evidence base.
Formulation and co-administration: Pterostilbene’s high lipophilicity means absorption is enhanced when taken with a fat-containing meal. Some commercial formulations combine it with nicotinamide riboside (e.g., Basis) or grape extract (which, in the Riche trial, attenuated the LDL increase).
Baseline metabolic status: Benefits on blood pressure and liver inflammation markers have been observed in individuals with pre-existing hypercholesterolemia (Riche 2014) or NAFLD (Dellinger 2023). Healthy adults with normal baseline biomarkers may see smaller absolute changes.
Age: The NRPT trials primarily enrolled adults aged 60–80. Benefits on NAD+ elevation may be more meaningful in older adults, whose baseline NAD+ levels are lower than those of younger individuals. Younger, metabolically healthy adults may derive less benefit from pterostilbene’s antioxidant and sirtuin mechanisms.
Genetic factors: Polymorphisms in Phase II metabolic enzymes including COMT (catechol-O-methyltransferase, involved in methylation of polyphenols), CYP1A2 (cytochrome P450 1A2, a liver enzyme metabolizing caffeine and many drugs), CYP3A4 (cytochrome P450 3A4, the most abundant liver enzyme, responsible for metabolizing approximately 50% of all drugs), and UGT (UDP-glucuronosyltransferase, enzymes that conjugate and inactivate drugs and polyphenols) family enzymes may influence individual pterostilbene metabolism, though this has not been characterized in human supplementation trials.
Sex-based differences: No significant sex-based differences in pterostilbene response have been reported in the existing human RCTs. Animal lifespan data (Drosophila) suggest pterostilbene extended lifespan in both sexes but via different gene-expression patterns, hinting at potential sex-specific mechanisms.
Concurrent cholesterol medication: In the Riche (2014) trial, participants on statins showed an attenuated LDL-raising effect from pterostilbene compared to unmedicated participants — an unexpected interaction suggesting statins may blunt pterostilbene’s effect on LDL receptor regulation.

Potential Risks & Side Effects

Medium 🟥 🟥

LDL Cholesterol Elevation

Riche et al. (2014) reported a significant 17.1 mg/dL increase in LDL cholesterol with pterostilbene monotherapy at 50 mg or 125 mg twice daily over 6–8 weeks in adults with hypercholesterolemia — statistically robust (p = 0.001). This effect was attenuated when pterostilbene was combined with grape extract (100 mg twice daily) and in participants taking cholesterol-lowering medication. The finding prompted ChromaDex, a major supplier of pterostilbene, to halt new orders at the time. Mechanistically, pterostilbene up-regulates LDL receptor expression in cardiomyocytes, but the net effect on circulating LDL in humans is adverse. This is the most consistently cited risk with pterostilbene supplementation.

Magnitude: LDL cholesterol +17.1 mg/dL over 6–8 weeks at 100–250 mg/day in hypercholesterolemic adults not on statin therapy. Effect attenuated by co-administration of grape extract or concurrent statin use.

Low 🟥

Gastrointestinal and Mild Systemic Effects

Pterostilbene has generally been well tolerated in clinical trials. Riche et al. (2013) explicitly evaluated safety over 6–8 weeks at up to 250 mg/day and found no significant adverse drug reactions on hepatic, renal, or glucose markers and no statistically significant self-reported adverse events. Mild gastrointestinal (GI) symptoms (nausea, soft stools) have been reported anecdotally at higher doses. The Otsuka et al. (2025) 12-week pilot study at 10 or 100 mg/day found no adverse events and no biochemical abnormalities.

Magnitude: Mild and generally comparable to placebo at ≤250 mg/day; limited data at higher doses.

Theoretical Drug Interactions

Like resveratrol, pterostilbene has the potential to modulate cytochrome P450 enzyme activity (notably CYP3A4, CYP1A2, CYP2D6 [cytochrome P450 2D6, a liver enzyme metabolizing roughly 25% of clinically used drugs including many antidepressants and beta blockers]) based on in vitro work, although pterostilbene has been less extensively characterized than resveratrol. It may theoretically enhance the effect of anticoagulants and antiplatelet drugs through stilbene-class platelet-inhibiting activity. Clinically documented interactions at typical supplemental doses are scarce.

Magnitude: Theoretically plausible; clinically quantified interactions are sparse.

Speculative 🟨

Hormone-Sensitive Tissues ⚠️ Conflicted

Pterostilbene, like resveratrol, exhibits mixed estrogenic/anti-estrogenic activity in vitro and can function as a selective estrogen receptor modulator. This raises theoretical concerns for individuals with hormone-sensitive cancers, although ongoing oncology trials (e.g., NCT03671811 in endometrial cancer) are specifically exploring pterostilbene’s anti-proliferative potential in hormone-responsive tumors. The direction of net clinical effect in humans remains unresolved.

Long-Term Safety Beyond Short-Term Trials

No human trials have extended beyond 6 months of continuous pterostilbene supplementation. Chronic multi-year safety, particularly in combination with other sirtuin-modulating compounds, has not been assessed.

Exercise Adaptation Blunting ⚠️ Conflicted

By analogy with resveratrol (Gliemann et al. 2013), there is theoretical concern that chronic high-dose polyphenol supplementation could blunt exercise-induced mitochondrial adaptations through antioxidant interference with redox signaling. Pterostilbene has not been directly studied in this context, and preliminary trial data (NCT07024966) combining pterostilbene with silybin and nicotinamide riboside suggest potential reduction in exercise-induced oxidative damage rather than adaptation blunting. The concern remains speculative for pterostilbene specifically.

Risk-Modifying Factors

Baseline lipid profile: Individuals with pre-existing hypercholesterolemia or elevated LDL are the group in whom the LDL-raising effect has been documented. Those with optimal lipids at baseline have not been specifically studied, and the net lipid effect in a normolipidemic population is unknown.
Concurrent cholesterol medication: Statin therapy appears to attenuate pterostilbene’s LDL-raising effect, though this is based on subgroup analysis from a single trial and should not be relied upon for cholesterol management.
Pre-existing liver disease: Individuals with NAFLD or elevated transaminases should be aware that NRPT (combination) data are mixed, with improvements in ALT/GGT but no change in hepatic fat fraction at the higher dose. Baseline liver function should be established and monitored.
Hormone-sensitive cancers: Individuals with active or prior hormone-sensitive cancers (breast, ovarian, endometrial, prostate) should discuss pterostilbene with their oncologist given the mixed in vitro estrogenic signal, though clinical harm has not been demonstrated.
Anticoagulant or antiplatelet therapy: Individuals on warfarin, direct oral anticoagulants (DOACs), aspirin, or clopidogrel should approach pterostilbene cautiously given the stilbene class’s theoretical antiplatelet activity.
Genetic polymorphisms: Variants in CYP1A2, CYP3A4, CYP2D6, and UGT family enzymes may affect pterostilbene metabolism and drug-interaction risk. These have not been characterized specifically for pterostilbene supplementation.
Sex-based differences: No significant sex-based safety differences have been reported in human trials, though trial populations have been modest in size.
Age: Older adults (60+) have been the primary study population for NRPT trials. The LDL-elevation trial enrolled adults with hypercholesterolemia (mean age 54). Adequacy of safety data in younger, healthy adults is limited.

Key Interactions & Contraindications

Statins and other lipid-lowering agents: Pterostilbene’s LDL-raising effect was attenuated in participants on cholesterol-lowering medication in the Riche (2014) trial. This is a clinically relevant directional interaction that complicates interpretation for individuals using lipid-lowering therapy.
Anticoagulants and antiplatelet drugs: Stilbenes have antiplatelet activity. Co-administration with warfarin, heparin, apixaban, rivaroxaban, aspirin, or clopidogrel may theoretically increase bleeding risk. International normalized ratio (INR, a measure of blood clotting time used to monitor anticoagulant therapy) monitoring should be considered when combining with warfarin.
CYP3A4 and CYP1A2 substrates: Pterostilbene may inhibit these hepatic enzymes based on in vitro data, potentially increasing plasma levels of statins (atorvastatin, simvastatin), calcium-channel blockers (amlodipine), immunosuppressants (cyclosporine, tacrolimus), and caffeine. Clinical magnitude at typical supplement doses is poorly characterized.
Nicotinamide riboside (NR): Pterostilbene is commercially combined with NR in the Basis formulation. The combination has been studied more extensively than pterostilbene monotherapy and reliably elevates NAD+. Whether this synergy improves outcomes beyond NR alone remains unclear.
Other polyphenols (resveratrol, quercetin, curcumin, EGCG [epigallocatechin gallate, the primary polyphenol in green tea]): Combination polyphenol supplementation can produce additive CYP inhibition and unpredictable interactions at high combined doses. Pterostilbene and resveratrol together have been proposed as synergistic, though controlled human data on the combination are lacking.
Blood pressure-lowering supplements and drugs: Pterostilbene at 250 mg/day produced clinically meaningful reductions in blood pressure. Combination with antihypertensive medications (ACE inhibitors [angiotensin-converting enzyme inhibitors, which relax blood vessels], ARBs [angiotensin II receptor blockers, another class of antihypertensives], beta blockers, diuretics), magnesium, CoQ10 (coenzyme Q10), omega-3 fatty acids, or potassium supplements may produce additive hypotensive effects.
Hormone-sensitive cancer therapies: Pterostilbene’s mixed estrogenic activity introduces theoretical interaction with tamoxifen, aromatase inhibitors, or endocrine therapies for prostate cancer. Oncology-directed trials of pterostilbene in these contexts are ongoing.
Populations who should avoid or defer pterostilbene supplementation:
- Individuals with elevated LDL cholesterol not on statin therapy, unless willing to monitor lipids closely.
- Pregnant and breastfeeding women (insufficient safety data).
- Individuals with hormone-sensitive cancers, absent oncologist guidance.
- Individuals with active bleeding disorders or on anticoagulant therapy without medical supervision.
- Individuals planning surgery should discontinue pterostilbene at least 1–2 weeks prior, by analogy with resveratrol.

Risk Mitigation Strategies

Baseline lipid panel: Obtain a fasting lipid panel before starting pterostilbene. Given the LDL-elevation signal, individuals with baseline LDL above optimal should either avoid pterostilbene or commit to repeat lipid testing at 6–8 weeks.
Co-administer with grape extract or within a mixed-polyphenol formulation: The Riche (2014) trial showed that combination with grape extract attenuated the LDL increase. Commercial pterostilbene products bundled with grape extract or other polyphenols may carry lower lipid risk than pterostilbene monotherapy.
Start at a conservative dose: Clinical trial doses have ranged from 50 mg to 250 mg/day. Starting at 50–100 mg/day allows tolerance assessment before escalation.
Avoid doses above 250 mg/day: Human safety data support up to 250 mg/day. Higher doses exceed the evidence base and are not recommended outside of research contexts.
Review medication interactions: Before starting pterostilbene, review concurrent medications — particularly statins, anticoagulants, antiplatelet drugs, antihypertensives, and CYP3A4/1A2 substrates — with a pharmacist or physician.
Monitor blood pressure: If already taking antihypertensive medications, monitor blood pressure when starting pterostilbene given its documented hypotensive effect at 250 mg/day. Dose adjustment of antihypertensives may occasionally be warranted.
Monitor liver enzymes: Although short-term safety data are reassuring, individuals with pre-existing liver disease or those on NRPT combinations should obtain baseline and 8–12 week liver function tests.
Discontinue before surgery: Stop pterostilbene at least 1–2 weeks before any planned surgical or dental procedure due to theoretical antiplatelet effects.
Set realistic expectations: Human outcome data remain limited. Pterostilbene’s documented benefits are modest (blood pressure, NAD+ elevation, secondary liver biomarkers) and the evidence for longevity, cognitive, or cancer-prevention effects is currently speculative.

Therapeutic Protocol

The protocol below reflects the doses used in published human trials and the approaches adopted by practitioners interested in stilbenoid supplementation. Where competing approaches exist — pterostilbene monotherapy, pterostilbene plus grape extract, or NRPT combination — the main options are presented without endorsement of one as default.

Dose (monotherapy): 50–250 mg/day in divided doses, with 100–250 mg/day corresponding to the dose range used in the Riche (2014) trial. Doses above 250 mg/day exceed published safety data.
Dose (NRPT combination — Basis-style): 50 mg pterostilbene plus 250 mg nicotinamide riboside once daily (the “1×” dose in Dellinger 2017/2023), or double that (“2×”) if targeting higher NAD+ elevation. The higher dose did not produce superior outcomes in NAFLD and should be considered experimental.
Dose (with grape extract): 50 mg pterostilbene plus 100 mg grape extract twice daily — the combination arm in Riche (2014) that did not increase LDL cholesterol. This represents the safer monotherapy alternative for individuals concerned about the lipid signal.
Competing therapeutic approaches: The three options above are supported by distinct evidence bases. NRPT has the most human data (Elysium Health / Guarente laboratory); pterostilbene-plus-grape-extract has a single RCT supporting its more favorable lipid profile; pterostilbene monotherapy has the clearest blood-pressure signal but the documented LDL elevation. No expert consensus exists on which approach is optimal.
Timing: Morning administration with breakfast (a fat-containing meal) is the most common approach in practice, supporting absorption of the lipophilic compound and avoiding any theoretical interference with evening circadian signaling. For twice-daily split dosing (as used in the Riche trials), morning and midday/early-evening (with meals) is preferred over late-evening dosing. No direct evidence ties a specific time of day to greater efficacy; Riche trials did not specify. Due to a plasma half-life estimated at 80–90 minutes (free pterostilbene, though metabolites persist longer), single daily dosing is typical; split (twice-daily) dosing was used in the Riche trials.
Half-life: Plasma half-life of free pterostilbene is approximately 80–120 minutes in humans, substantially longer than free resveratrol but still consistent with once- or twice-daily dosing.
Single vs. split dosing: Split (twice-daily) dosing was used in the Riche trials; single daily dosing is used in NRPT products. Both approaches appear reasonable.
Genetic considerations: No pharmacogenomic dosing guidance exists for pterostilbene. Variants in CYP3A4, CYP1A2, and UGT family enzymes may theoretically influence individual response.
Sex-based considerations: No evidence supports different dosing for men vs. women.
Age considerations: NRPT trials have primarily enrolled adults aged 60–80. Benefits may be more evident in older adults; younger adults should have modest expectations.
Baseline biomarkers: Fasting lipid panel, blood pressure, liver enzymes, and (optionally) NAD+ testing provide useful references for tracking response.
Pre-existing conditions: Individuals with hypercholesterolemia should favor the grape-extract combination or defer supplementation. Those with NAFLD may consider NRPT under medical supervision given the liver-enzyme improvement signal.

Discontinuation & Cycling

Lifelong vs. short-term: Pterostilbene is typically used as an ongoing supplement rather than in defined cycles.
Withdrawal effects: No human data demonstrate dependence, tolerance, or withdrawal effects upon discontinuation. The biomarker effects observed in trials — blood pressure reduction, LDL elevation, NAD+ increase, hepatic enzyme improvement — would be expected to regress within days to weeks after stopping, as plasma levels decline.
Tapering: Tapering is not necessary.
Cycling: Some practitioners favor periodic breaks (e.g., 1 month off after 3 months on) as a precaution given the limited long-term safety data, though this is not evidence-based. Cycling is not required to maintain efficacy based on available pharmacokinetic and biomarker evidence.
Chronic use monitoring: For individuals using pterostilbene chronically, periodic reassessment of lipid panel and liver enzymes every 6 months is reasonable.

Sourcing and Quality

Formulation selection: Most commercial pterostilbene products are synthetic or semi-synthetic, with purity specifications typically ≥97–99%. Trans-pterostilbene is the biologically active isomer; reputable products specify trans content.
What to look for: Select products third-party tested (USP, NSF International, or ConsumerLab where applicable) for purity, label accuracy, and absence of contaminants. Products should specify dosage per capsule, trans-isomer content, and source (natural extract vs. synthetic).
Combination products: The most extensively studied pterostilbene combinations are (a) Basis (Elysium Health), combining 50 mg pterostilbene with 250 mg nicotinamide riboside; and (b) pterostilbene plus grape extract, as used in the Riche (2014) favorable-lipid arm. Products marketed solely for sirtuin/longevity support may contain pterostilbene alongside resveratrol or other polyphenols.
Reputable brands: Life Extension pTeroPure, Double Wood Supplements Pterostilbene, Jarrow Formulas pTerostilbene, Thorne pTerostilbene, and Elysium Basis are among brands with established quality reputations or ingredient-supplier transparency (most reputable products use ChromaDex’s pTeroPure or similar pharmaceutical-grade synthesized pterostilbene).
Storage: Pterostilbene is light-sensitive, like resveratrol, and should be stored in opaque containers in a cool, dry environment. Capsules are preferred over powder for stability.
Purity considerations: Ensure products specify the source of pterostilbene (synthetic vs. Pterocarpus marsupium extract vs. grape/berry extract). Synthetic high-purity pterostilbene dominates the supplement market and is the form used in most clinical trials.

Practical Considerations

Time to effect: Blood pressure reductions were observable by 6–8 weeks in the Riche (2014) trial. NAD+ elevation with NRPT was significant by 4 weeks. Subjective effects, where reported, are often vague and may reflect placebo or concurrent lifestyle changes.
Common pitfalls: The most significant pitfall is undertaking pterostilbene supplementation without obtaining a baseline lipid panel and being unaware of the LDL-elevation signal. A second common mistake is assuming pterostilbene’s bioavailability advantage over resveratrol translates automatically into proportionally larger clinical benefits, which is not supported by current human evidence. A third is expecting the sirtuin/longevity benefits extensively demonstrated in cell and animal studies to manifest in healthy adults — no human outcome data support this. Finally, consumers often conflate pterostilbene alone with the NRPT combination, which has a distinct evidence base.
Regulatory status: Pterostilbene is sold as a dietary supplement in the United States. It has GRAS (Generally Recognized As Safe) self-affirmed status for certain uses at defined dose ranges. It is not approved as a drug for any indication.
Cost: Pterostilbene monotherapy supplements typically cost $15–40/month for 50–150 mg daily doses. NRPT products (e.g., Basis) are substantially more expensive at roughly $50–60/month given the nicotinamide riboside content. Pterostilbene is not exceptionally expensive relative to other longevity-oriented polyphenols.

Interaction with Foundational Habits

Sleep: Pterostilbene has no established direct effects on sleep architecture, circadian rhythms, or melatonin. It does not cause drowsiness or stimulation. In vitro evidence suggests stilbenoids may interact with circadian clock mechanisms, but this has not translated to observable human sleep effects. Pterostilbene can be taken at any time of day; taking with breakfast or lunch is common given the long day for metabolite persistence.
Nutrition: Pterostilbene is found naturally in blueberries (approximately 99 ng per gram in fresh berries — a fraction of supplement doses), grapes, almonds, and Pterocarpus marsupium heartwood. Dietary intake is negligible compared to supplemental doses. Supplementation should be paired with a fat-containing meal to optimize absorption of this lipophilic compound. A polyphenol-rich diet (berries, nuts, tea) may provide complementary antioxidant and anti-inflammatory effects, though additive interactions at high combined supplement doses (quercetin, resveratrol, curcumin) may amplify CYP inhibition.
Exercise: No direct human trials have evaluated pterostilbene’s effect on exercise adaptation. A current trial (NCT07024966) is examining a pterostilbene-silybin-nicotinamide riboside combination for exercise-induced oxidative stress, suggesting the hypothesis that pterostilbene may reduce exercise damage rather than blunt adaptation. By analogy with resveratrol, chronic high-dose antioxidant polyphenol supplementation theoretically could blunt mitochondrial adaptations, but this has not been demonstrated for pterostilbene specifically. Moderate doses (≤150 mg/day) taken at least several hours from workouts represent a conservative approach for physically active individuals.
Stress management: Pterostilbene’s anti-inflammatory and antioxidant activity may indirectly support stress resilience by reducing inflammatory markers elevated under chronic psychological stress. Pterostilbene does not directly modulate cortisol or the HPA (hypothalamic-pituitary-adrenal, the body’s central stress response system) axis in documented human data. Supplementation does not substitute for core stress-management practices.

Monitoring Protocol & Defining Success

Baseline labs should be obtained before starting pterostilbene, with follow-up at 8–12 weeks and then every 6 months during continued use. The lipid panel is particularly important given the LDL signal.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Lipid panel (fasting)	LDL < 100 mg/dL, HDL > 50 mg/dL, triglycerides < 100 mg/dL	Track primary pterostilbene safety signal (LDL elevation)	LDL = low-density lipoprotein; HDL = high-density lipoprotein. The Riche (2014) trial documented +17.1 mg/dL LDL with pterostilbene monotherapy. Fasting required. Conventional reference LDL < 130 mg/dL. Recheck at 6–8 weeks
Blood pressure	< 120/80 mmHg	Monitor documented hypotensive effect, especially if on antihypertensives	Measure at rest, same time of day. Conventional target < 140/90 mmHg. −7.8/−7.3 mmHg at 250 mg/day per Riche 2014
ALT and AST	ALT < 25 U/L, AST < 25 U/L	Monitor hepatic safety and track NRPT benefit signal if applicable	ALT = alanine aminotransferase; AST = aspartate aminotransferase. NRPT reduced ALT and GGT in NAFLD (Dellinger 2023). Standard reference < 35–40 U/L. Routine panel
GGT	< 25 U/L	Secondary hepatic marker, responsive to NRPT	GGT = gamma-glutamyl transferase. Conventional range < 50–60 U/L. Particularly relevant for individuals using NRPT for liver health
Fasting glucose and HbA1c	Glucose 72–85 mg/dL, HbA1c < 5.4%	Track metabolic response; no adverse signal to date but prudent monitoring	HbA1c = glycated hemoglobin, a marker of average blood glucose over 2–3 months. Conventional HbA1c < 5.7% normal. Fasting required for glucose
Whole-blood NAD+ (optional)	Individualized	Confirm biomarker response if using NRPT	Specialty test, not widely available through routine labs. NRPT increased NAD+ +40% at recommended dose (Dellinger 2017)
hs-CRP	< 1.0 mg/L	Track systemic inflammation as a functional outcome	hs-CRP = high-sensitivity C-reactive protein. Conventional range < 3.0 mg/L. Avoid testing during acute illness
Complete blood count (CBC) and comprehensive metabolic panel (CMP)	Within reference	General safety monitoring	CBC and CMP = complete blood count and comprehensive metabolic panel, both standard screening panels. Routine panels; include to screen for unexpected effects

Monitoring frequency: baseline, 8–12 weeks, then every 6 months.

Qualitative markers: Subjective measures that may accompany response include home blood-pressure trends (most actionable), energy levels, cognitive clarity, exercise recovery, and general inflammatory symptoms (joint comfort, skin, digestion). These are secondary to the objective lipid and blood pressure measurements.

Emerging Research

Several ongoing or recently reported trials address pterostilbene directly or in combination:

The NO-ALS trial (NCT04562831) is a 380-participant study evaluating EH301 (nicotinamide riboside plus pterostilbene) in amyotrophic lateral sclerosis across multiple Norwegian centers. Its extension study (NCT05095571) follows patients for long-term adverse-event and disease-progression outcomes.
A phase 2 endometrial cancer trial (NCT03671811) is evaluating pterostilbene as an adjunct to megestrol acetate before hysterectomy in 44 patients with atypical endometrial hyperplasia or endometrial carcinoma, testing whether pterostilbene enhances anti-proliferative effects.
A combined NAC + EH-301 ALS trial (NCT07414212) is enrolling 90 ALS patients in a 2025–2026 phase 1/2 study of N-acetylcysteine combined with the NR-pterostilbene combination, with riluzole as background therapy.
An exercise oxidative-stress trial (NCT07024966) is studying a pterostilbene-silybin-nicotinamide riboside combination in 14 healthy men in a crossover design, measuring oxidative DNA damage and muscle-damage markers after high-intensity exercise — informative for the exercise-adaptation question.
Ongoing research is evaluating whether pterostilbene’s modulation of the PCSK9/HNF1α/SREBP2/LDLR axis — established in cardiomyocytes — can reconcile the paradoxical LDL increase seen in the Riche (2014) trial. Follow-up human trials of pterostilbene with concurrent lipid-handling measurement would directly test this.
Research directions that could strengthen the case for pterostilbene include larger trials focused on cardiovascular endpoints in populations already on statins (where LDL elevation is attenuated), dedicated NAD+ outcome studies comparing NRPT with nicotinamide riboside monotherapy, and controlled trials in neurodegenerative disease that are adequately powered for clinical endpoints rather than biomarkers.
Research directions that could weaken the case include replication trials confirming the LDL-elevation signal in broader populations, direct mechanistic studies establishing whether human-achievable plasma pterostilbene concentrations produce meaningful sirtuin activation, and long-term safety studies examining chronic supplementation beyond 6 months.

Conclusion

The human evidence base for pterostilbene is narrow in volume and short in duration. A handful of randomized controlled trials — spanning weeks to six months — constitute the clinical foundation, with no systematic reviews or meta-analyses of meaningful human outcome data. The research is heavily weighted toward mechanistic and preclinical findings, and several of the key human trials have been conducted or funded by parties with commercial interests in pterostilbene-containing products. Hard clinical endpoints — cardiovascular events, lifespan, cognitive decline — have not been studied. Gaps are substantial across nearly every proposed benefit domain.

The evidence in favor of pterostilbene centers on two areas with controlled human data. Pterostilbene monotherapy produced a clinically meaningful reduction in blood pressure — among the larger magnitudes reported for a polyphenol supplement. When combined with nicotinamide riboside, the formulation reliably and reproducibly elevated whole-blood levels of a key cellular energy cofactor over eight weeks. Secondary analyses in fatty liver disease observed reductions in liver inflammation markers at one dose level, suggesting possible hepatic activity.

The evidence against pterostilbene or in favor of caution is equally substantial. The most prominent finding is a statistically robust elevation in LDL cholesterol with monotherapy — a result whose mechanism remains incompletely understood and whose generalizability beyond hypercholesterolemic adults is untested. The primary endpoint in the fatty liver trial was not met, and the higher dose produced no improvement. No human data support longevity, cognitive, or anti-cancer effects. Safety beyond six months is uncharacterized, and potential interactions with anticoagulants and hepatically metabolized drugs remain theoretically plausible but clinically unquantified.

Top - Benefits - Risks - Protocol

Pterostilbene for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Medium 🟩 🟩

Blood Pressure Reduction

NAD+ Elevation (as Part of NRPT Combination)

Low 🟩

Hepatic Inflammation Reduction in NAFLD ⚠️ Conflicted

Antioxidant and Anti-Inflammatory Activity

Speculative 🟨

Sirtuin Activation & Longevity Pathway Modulation ⚠️ Conflicted

Cognitive Function & Neuroprotection ⚠️ Conflicted

Anti-Cancer Properties ⚠️ Conflicted

Skin Photoaging & Cosmetic Benefits

Benefit-Modifying Factors

Potential Risks & Side Effects

Medium 🟥 🟥

LDL Cholesterol Elevation

Low 🟥

Gastrointestinal and Mild Systemic Effects

Theoretical Drug Interactions

Speculative 🟨

Hormone-Sensitive Tissues ⚠️ Conflicted

Long-Term Safety Beyond Short-Term Trials

Exercise Adaptation Blunting ⚠️ Conflicted

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion